Concept · medicine
Ferroptosis
Follow Ferroptosis — see important new research and changes in evidence.Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published
Ferroptosis is iron-dependent regulated cell death driven by phospholipid peroxidation—distinct from apoptosis—often tracked through ACSL4-enriched oxidizable membranes and GPX4-dependent peroxide detoxification.
Students meet ferroptosis in both organ-injury and cancer contexts. Critical-care models ask whether restraining ferroptosis protects tissue; oncology asks whether triggering it kills resistant cells. Those are opposite therapeutic directions on the same pathway.
Evidence
What the evidence shows
Drawn from 4 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Dexmedetomidine can protect mouse kidneys after I/R in an ACSL4/ferroptosis-linked framing.
In a renal ischemia/reperfusion mouse model, dexmedetomidine improved Scr/BUN and was tested as acting by inhibiting ACSL4-linked ferroptosis and inflammation via α2-AR signaling.
- Which cell-death programs drive septic acute lung injury?— pathway review across autophagy/ferroptosis/pyroptosis — not the same Dex I/R experiment
Study Role Design N Population Outcome Does ICU sedative Dex blunt kidney ferroptosis after I/R? Supports Animal / in-vitroMouse bilateral renal I/R (45 min/48 h) plus HEK293T OGD/R with Dex and ACSL4/α2-AR manipulations Multiple animal/cell assay groups; no single primary clinical N C57BL/6 mice and HEK293T cells under renal I/R or OGD/R stress Ferroptosis, inflammation, and ACSL4 signaling after Dex via α2-AR Which cell-death programs drive septic acute lung injury? Qualifiespathway review across autophagy/ferroptosis/pyroptosis — not the same Dex I/R experiment OtherNarrative mechanistic review of autophagy, ferroptosis, and pyroptosis literature in LPS/CLP sepsis-induced ALI (not a new primary experiment) No primary analytic N; synthesizes published LPS/CLP and related studies Published preclinical (and cited clinical framework) literature on sepsis-induced ALI/ARDS Mapped death-pathway mechanisms and candidate pharmacologic targets for septic lung injury Sepsis ALI literature treats ferroptosis as one interconnected injury program among others.
A sepsis-induced ALI review argues lung injury may be attenuated by regulating autophagy, ferroptosis, and pyroptosis across shared nodes (including ACSL4 and GPX4-axis signaling).
- Does ICU sedative Dex blunt kidney ferroptosis after I/R?— single-agent mouse I/R study — not a sepsis ALI trial
Study Role Design N Population Outcome Which cell-death programs drive septic acute lung injury? Supports OtherNarrative mechanistic review of autophagy, ferroptosis, and pyroptosis literature in LPS/CLP sepsis-induced ALI (not a new primary experiment) No primary analytic N; synthesizes published LPS/CLP and related studies Published preclinical (and cited clinical framework) literature on sepsis-induced ALI/ARDS Mapped death-pathway mechanisms and candidate pharmacologic targets for septic lung injury Does ICU sedative Dex blunt kidney ferroptosis after I/R? Qualifiessingle-agent mouse I/R study — not a sepsis ALI trial Animal / in-vitroMouse bilateral renal I/R (45 min/48 h) plus HEK293T OGD/R with Dex and ACSL4/α2-AR manipulations Multiple animal/cell assay groups; no single primary clinical N C57BL/6 mice and HEK293T cells under renal I/R or OGD/R stress Ferroptosis, inflammation, and ACSL4 signaling after Dex via α2-AR Triggering tumor ferroptosis can help checkpoint therapy in cold tumors (preclinical).
In EGFR-mutant NSCLC models, cisplatin-driven tumor ferroptosis polarized N1 neutrophils and supported T-cell/Th1 programs that synergized with immune checkpoint inhibitor therapy.
- Does blocking IRE1/JNK calm ferroptosis in AKI?— renal protection restrains ferroptosis — opposite therapeutic direction from oncology induction
Blocking IRE1/JNK can attenuate ferroptosis-linked renal I/R injury in mice/cells.
Renal ischemia/reperfusion activated IRE1/JNK with ferroptotic tubular injury; inhibiting that axis improved BUN/creatinine and ferroptosis markers, aligning with ferrostatin-1-style protection.
- Does ICU sedative Dex blunt kidney ferroptosis after I/R?— another renal I/R ferroptosis-protection model — different drug/node (Dex/ACSL4 vs IRE1/JNK)
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
A mouse renal I/R pharmacologic result and a sepsis ALI pathway review do not establish how much ferroptosis dominates human critical illness versus apoptosis/pyroptosis.
- Does ICU sedative Dex blunt kidney ferroptosis after I/R?
- Which cell-death programs drive septic acute lung injury?
Study Role Design N Population Outcome Does ICU sedative Dex blunt kidney ferroptosis after I/R? Supports Animal / in-vitroMouse bilateral renal I/R (45 min/48 h) plus HEK293T OGD/R with Dex and ACSL4/α2-AR manipulations Multiple animal/cell assay groups; no single primary clinical N C57BL/6 mice and HEK293T cells under renal I/R or OGD/R stress Scr/BUN and ferroptosis/ACSL4 readouts after renal I/R Which cell-death programs drive septic acute lung injury? Supports OtherNarrative mechanistic review of autophagy, ferroptosis, and pyroptosis literature in LPS/CLP sepsis-induced ALI (not a new primary experiment) No primary analytic N; synthesizes published LPS/CLP and related studies Published preclinical (and cited clinical framework) literature on sepsis-induced ALI/ARDS Narrative map of cell-death pathways in sepsis ALI Cisplatin-induced ferroptosis aided ICI efficacy in cold tumors vs IRE1/JNK blockade reduced ferroptosis-linked kidney I/R injury
Common misconceptions
Ferroptosis is just another name for apoptosis.
It is iron-dependent lipid-peroxidation death with distinct regulators (e.g., ACSL4/GPX4).
Any drug that mentions ferroptosis is proven in patients.
Many claims remain preclinical; human contribution vs other death modes is still debated.
Ferroptosis drugs always protect tissue.
Oncology strategies may deliberately induce ferroptosis; organ-injury models often try to block it.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
Name two ferroptosis-related nodes often paired in pathway maps.
ACSL4 and GPX4 (Xc–GSH–GPX4 axis).
Why can oncology and critical care ‘want’ opposite ferroptosis directions?
Cancer therapy may want to trigger it; organ protection may want to restrain it.
Give one oncology vs one organ-injury ferroptosis goal from this library.
Induce ferroptosis to aid ICI (cisplatin/N1 neutrophil models); restrain ferroptosis in renal I/R (IRE1/JNK or Dex/ACSL4 models).
The studies
4 studies in this library bear on Ferroptosis, ordered by citations.
- Does ICU sedative Dex blunt kidney ferroptosis after I/R?
In mice and kidney cells, dexmedetomidine lessened ferroptosis-linked renal I/R injury by restraining ACSL4 through α2-AR.
- How does cisplatin boost checkpoint therapy?
Cisplatin-triggered tumor ferroptosis polarized N1 neutrophils and remodeled cold NSCLC tumors toward hotter T-cell/Th1 states, synergizing with ferroptosis activators in EGFR-mutant settings.
- Does blocking IRE1/JNK calm ferroptosis in AKI?
In I/R mice and H/R HK-2 cells, IRE1/JNK activation tracked with ferroptosis; inhibiting the pathway improved BUN/creatinine and ferroptosis markers.
- Which cell-death programs drive septic acute lung injury?
This review maps how unbalanced autophagy, ferroptosis, and pyroptosis worsen sepsis-induced ALI and which drugs might retune them.